Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Neoplasms by Site 1Neoplasms 1Lung Neoplasms 1Lung Diseases 1KRAS p, G12c Mutated /Advanced Metastatic NSCLC 1Hereditary Sensory and Autonomic Neuropathies 1Healthy Participants 1Carcinoma 1Bronchial Neoplasms 1Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation 1

Interventions

selpercatinib 2pralsetinib 2sotorasib 1pembrolizumab 1patritumab 1osimertinib 1durvalumab 1cobimetinib 1alectinib 1Tyrosine Kinase Inhibitors 1Radiosurgery 1Pemetrexed 1Paclitaxel 1Gemcitabine 1Erlotinib Hydrochloride 1Dasatinib 1Cisplatin 1Carboplatin 1Afatinib 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Respiratory Tract Diseases × sotorasib × Clear all
NCT05054725 2026-01-06

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Revolution Medicines, Inc.

Phase 2 Completed
47 enrolled 17 charts
Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Respiratory Tract Diseases, Respiratory Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡